MedTrace Logo

Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines

NCT03368495 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 851

Last updated 2019-05-21

No results posted yet for this study

Summary

This study evaluates seroconversion against measles, mumps, rubella and yellow fever following vaccination. One-third of children will receive both yellow fever and measles, mumps, and rubella (MMR) vaccines on the same day; one- third of children will receive MMR vaccine at enrollment followed by yellow fever vaccine 4 weeks later; one-third of children will receive yellow fever vaccine at enrollment followed by MMR vaccine 4 weeks later.

Conditions

  • Vaccine Response Impaired

Interventions

BIOLOGICAL

Co-administration of MMR/YF

Both MMR \& yellow fever vaccines administered on Day 0.

BIOLOGICAL

MMR followed by YF

MMR vaccine administered on Day 0 and yellow fever vaccine administered on Day 28.

BIOLOGICAL

YF followed by MMR

Yellow fever vaccine administered on Day 0 and MMR vaccine administered on Day 28.

Sponsors & Collaborators

Principal Investigators

  • Cristian Biscayart, MD · Minsterio de Salud de la Nacion, Argentina

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Months
Max Age
24 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-23
Primary Completion
2018-06-30
Completion
2018-06-30

Countries

  • Argentina

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03368495 on ClinicalTrials.gov